Loading data...
Loading data...
Pharmaceuticals, biotech, medical devices, and health insurance.
Healthcare combines two very different worlds: established pharmaceutical and health-insurance companies with stable cash flow and dividends, versus research-stage biotech companies whose success or failure hinges on a single event — a clinical trial or FDA approval or rejection. That distinction drives very different risk profiles between companies inside the same sector.
76.3
Average sector score
6
Stocks analyzed
| # | Company | Score | Rating | Price | Change | |
|---|---|---|---|---|---|---|
| 1 | Kamada Ltd. KMDA | 85 | Strong | $8.85 | +2.1% | Analysis → |
| 2 | Eupraxia Pharmaceuticals Inc. EPRX | 75 | Strong | $8.58 | +2.4% | Analysis → |
| 3 | Generate Biomedicines, Inc. GENB | 75 | Strong | $17.14 | +0.1% | Analysis → |
| 4 | TG Therapeutics, Inc. TGTX | 75 | Strong | $56.87 | +0.7% | Analysis → |
| 5 | Harmony Biosciences Holdings, Inc. HRMY | 75 | Strong | $42.02 | -1.7% | Analysis → |
| 6 | Aurinia Pharmaceuticals Inc - Common AUPH | 73 | Strong | $16.90 | -0.4% | Analysis → |
| 7 | Guardant Health, Inc. GH | 65 | Moderate | $179.38 | -2.0% | Analysis → |
| 8 | Thermo Fisher Scientific TMO | 65 | Moderate | $651.45 | -1.0% | Analysis → |
Because much of its value depends on a single regulatory event (clinical trial results, an FDA decision) that can dramatically change its business prospects overnight.
No — an established health-insurance or pharma company with stable cash flow is very different from a trial-stage biotech with no meaningful revenue.